136 related articles for article (PubMed ID: 8893835)
1. Three-dimensional models for agonist and antagonist complexes with beta 2 adrenergic receptor.
Kontoyianni M; DeWeese C; Penzotti JE; Lybrand TP
J Med Chem; 1996 Oct; 39(22):4406-20. PubMed ID: 8893835
[TBL] [Abstract][Full Text] [Related]
2. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.
Rosenbaum DM; Cherezov V; Hanson MA; Rasmussen SG; Thian FS; Kobilka TS; Choi HJ; Yao XJ; Weis WI; Stevens RC; Kobilka BK
Science; 2007 Nov; 318(5854):1266-73. PubMed ID: 17962519
[TBL] [Abstract][Full Text] [Related]
3. Biochemistry. Signaling across the cell membrane.
Ranganathan R
Science; 2007 Nov; 318(5854):1253-4. PubMed ID: 18033872
[No Abstract] [Full Text] [Related]
4. Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists.
Furse KE; Lybrand TP
J Med Chem; 2003 Oct; 46(21):4450-62. PubMed ID: 14521408
[TBL] [Abstract][Full Text] [Related]
5. A model of the adrenergic beta-2 receptor and binding sites for agonist and antagonist.
Lewell XQ
Drug Des Discov; 1992; 9(1):29-48. PubMed ID: 1360841
[TBL] [Abstract][Full Text] [Related]
6. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
7. A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors.
Gouldson PR; Snell CR; Reynolds CA
J Med Chem; 1997 Nov; 40(24):3871-86. PubMed ID: 9397168
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
9. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine.
Glennon RA; Dukat M; Westkaemper RB; Ismaiel AM; Izzarelli DG; Parker EM
Mol Pharmacol; 1996 Jan; 49(1):198-206. PubMed ID: 8569707
[TBL] [Abstract][Full Text] [Related]
10. Binding of agonists and antagonists to beta-adrenergic receptor.
Miklavc A; Kocjan D; Hadzi D; Mavri J; Koller J
Prog Clin Biol Res; 1989; 291():275-80. PubMed ID: 2567011
[No Abstract] [Full Text] [Related]
11. Insights into signaling from the beta2-adrenergic receptor structure.
Audet M; Bouvier M
Nat Chem Biol; 2008 Jul; 4(7):397-403. PubMed ID: 18560432
[TBL] [Abstract][Full Text] [Related]
12. Modeling GPCR active state conformations: the β(2)-adrenergic receptor.
Simpson LM; Wall ID; Blaney FE; Reynolds CA
Proteins; 2011 May; 79(5):1441-57. PubMed ID: 21337626
[TBL] [Abstract][Full Text] [Related]
13. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Baker JG; Hall IP; Hill SJ
Mol Pharmacol; 2003 Dec; 64(6):1357-69. PubMed ID: 14645666
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation.
Rubenstein LA; Zauhar RJ; Lanzara RG
J Mol Graph Model; 2006 Dec; 25(4):396-409. PubMed ID: 16574446
[TBL] [Abstract][Full Text] [Related]
15. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery.
Topiol S; Sabio M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1598-602. PubMed ID: 18243704
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
Procopiou PA; Barrett VJ; Bevan NJ; Biggadike K; Box PC; Butchers PR; Coe DM; Conroy R; Emmons A; Ford AJ; Holmes DS; Horsley H; Kerr F; Li-Kwai-Cheung AM; Looker BE; Mann IS; McLay IM; Morrison VS; Mutch PJ; Smith CE; Tomlin P
J Med Chem; 2010 Jun; 53(11):4522-30. PubMed ID: 20462258
[TBL] [Abstract][Full Text] [Related]
17. Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.
Reynolds KA; Katritch V; Abagyan R
J Comput Aided Mol Des; 2009 May; 23(5):273-88. PubMed ID: 19148767
[TBL] [Abstract][Full Text] [Related]
18. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor.
Gouldson PR; Kidley NJ; Bywater RP; Psaroudakis G; Brooks HD; Diaz C; Shire D; Reynolds CA
Proteins; 2004 Jul; 56(1):67-84. PubMed ID: 15162487
[TBL] [Abstract][Full Text] [Related]
19. Towards a thermodynamic definition of efficacy in partial agonism: The thermodynamics of efficacy and ligand proton transfer in a G protein-coupled receptor of the rhodopsin class.
Broadley KJ; Sykes SC; Davies RH
Biochem Pharmacol; 2010 Nov; 80(10):1537-45. PubMed ID: 20727346
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and beta-adrenergic activity of new completely aliphatic 3-(methyleneaminoxy)propanolamine derivatives.
Balsamo A; Gentili D; Lapucci A; Macchia M; Martinelli A; Orlandini E; Ferni G; Pinza M
Farmaco; 1994 Dec; 49(12):759-66. PubMed ID: 7893332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
